What is ForSight Robotics?
ForSight Robotics is a pioneering force in the field of robotic ophthalmic surgery, dedicated to redefining the standards of vision care. At the core of its technological portfolio is ORYOM, a next-generation surgical system engineered to enhance precision, safety, and efficiency in delicate eye procedures. By integrating sophisticated robotics with advanced imaging and control software, the company aims to mitigate human error and improve patient outcomes on a global scale.
The firm operates at the intersection of robotics, artificial intelligence, and ophthalmology, positioning itself as a critical player in the digital transformation of surgical suites. With a focus on high-acuity procedures, ForSight Robotics is effectively addressing the growing demand for minimally invasive, high-precision surgical solutions in an aging global population.
How much funding has ForSight Robotics raised?
ForSight Robotics has raised a total of $190M across 3 funding rounds:
Angel/Seed
$10M
Series A
$55M
Series B
$125M
Angel/Seed (2021): $10M with participation from MITHRIL CAPITAL PLC and Eclipse Ventures Incorporated
Series A (2022): $55M led by Adani, MITHRIL CAPITAL, and Eclipse Ventures
Series B (2025): $125M supported by Eclipse Automation and Adani
Key Investors in ForSight Robotics
Eclipse Ventures
A venture capital firm focused on backing early-stage companies that are building the physical world through advanced technology and industrial innovation.
Adani
A diversified conglomerate with extensive interests in infrastructure, energy, and logistics, providing strategic industrial support to high-growth technology ventures.
MITHRIL CAPITAL
An investment vehicle focused on identifying and scaling high-potential acquisition targets within the technology, media, and telecommunications sectors.
What's next for ForSight Robotics?
With the successful closure of this major enterprise-level funding, ForSight Robotics is well-positioned to accelerate its research and development initiatives and expand its commercial footprint. The strategic allocation of this capital will likely focus on scaling manufacturing capabilities, navigating regulatory pathways for international market entry, and deepening its clinical evidence base through multi-center trials.
Looking ahead, the company is expected to prioritize the integration of its ORYOM platform into major hospital networks and surgical centers. By maintaining a focus on technological superiority and clinical efficacy, ForSight Robotics is poised to disrupt the traditional ophthalmic surgery market, setting a new benchmark for automated surgical intervention and long-term vision health.
